Recorded live at Antibody Engineering & Therapeutics in San Diego, Episode 3 of Antibodies! brings together leading voices from across the antibody discovery and development community for a series of conversations on some of the field’s most important challenges and opportunities.
Hosted by Jonathan Davis, PhD, Founder of Creative Antibodies, this special conference edition features discussions on target discovery, tumor specificity, bispecific and trispecific antibodies, intracellular targets, antibody developability, Fc effector functions, nanobody discovery, and the growing role of artificial intelligence in antibody research.
Featured guests include:
Katherine Harris, PhD, Chief Development, Rondo Therapeutics; President, The Antibody Society
Bryan Glaser, PhD, Senior Vice President of Business Development Invenra
Bassil Dahiyat, PhD, President & Chief Executive Officer, Director, Xencor
Jay M. Bhatt, Principal Scientist, Johnson & Johnson Innovative Medicine
Shashi Jatiani, PhD, Director of Strategic Partnerships, SeromYx Systems
Brandon DeKosky, PhD Associate Professor at MIT and The Ragon Institute/MGH
Chris Szent Gyorgyi, PhD
From emerging antibody formats and next generation targeting strategies to AI enabled discovery and developability assessment, this episode offers a snapshot of the ideas shaping the future of antibody therapeutics.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Antibody Society. Innehållet i podden är skapat av The Antibody Society och inte av,
eller tillsammans med, Poddtoppen.
